Can a Plant-Based compound boost good cholesterol in High-Risk patients?

NCT ID NCT04941599

Recruiting now Disease control Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether a drug called 2-HOBA can improve the function of HDL (good cholesterol) in people with familial hypercholesterolemia, an inherited condition causing very high cholesterol. Researchers will give 72 participants either 2-HOBA or a placebo for six weeks. The goal is to see if 2-HOBA helps HDL remove cholesterol from cells more effectively, potentially lowering heart disease risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 2-Hydroxybenzylamine (2-HOBA)
What this could lead to: If it works, this could point toward a way to improve cholesterol management and reduce heart disease risk in people with familial hypercholesterolemia.
What could go wrong: This is an early Phase 2 trial with only 72 participants, so results may not apply broadly. The drug may not improve HDL function as hoped, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FAMILIAL HYPERCHOLESTEROLEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

familial hypercholesterolemia Hyperlipoproteinemia Type II

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FAMILIAL HYPERCHOLESTEROLEMIA

Contacts and locations

Locations

Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.